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ABSTRACT
Sexually active young men are at high risk of contracting HPV and developing genital
warts and penile/anal cancers. They contribute significantly to the incidence of HPV in women.
The HPV vaccine, Gardasil, was approved in 2009 for use in preventing HPV 6 and 11 in young
males ages 9 to 26. Knowledge and awareness of the virus and the vaccine is limited among
young men. Promoting education and prevention measures regarding HPV and reducing
personal risks to HPV is significant in narrowing the gap between acquisition of the HPV virus
and cancer sequelae. A correlational design utilizing cross-sectional survey methodology was
used for this study. Seventy participants completed a HPV vaccine survey at a university in
Southwestern United States. The survey measured their knowledge and acceptance of the HPV
vaccine and their intention to be vaccinated. Male participants were likely to accept or consent
to receive the vaccine however they reported low intent to actually get the HPV vaccine.
Acceptance of the vaccine was greater among minorities and participants who reported regular
doctor visits. Knowledge of HPV and HPV prevention was low. Young men may benefit from
HPV vaccine educational marketing strategies that include enhancing their communication skills
on HPV, the HPV vaccine and reducing risky sex behaviors.
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CHAPTER I: INTRODUCTION
Awareness of Human Papillomavirus (HPV) related cancers has continuously grown
around the United States, and the link between HPV and cervical cancer has been well
documented. HPV is prevalent among young sexually active adults and is currently the most
common sexually transmitted infection (STI) worldwide, causing cervical cancer, penile cancer,
anal cancer and an increasing number of squamous cell carcinomas at specific sites (Cubie,
2013). Cervical cancer is attributable to infection with two high risk subtypes of HPV, HPV 16
and HPV 18, which account for about 70% of all cases (Whyte, 2012). HPV infection is
generally asymptomatic, however it can manifest as genital warts in men and women. High risk
HPV 16 and 18 are linked to cervical cancer in women and penile cancer in men (Jones, & Cook,
2008; Centers for Disease Control and Prevention [CDC], 2013). Cervical cancer was one of the
most common types cancer deaths for women worldwide (American Cancer Society, 2014).
Approximately, 80% of females have been exposed to the HPV virus by age 50 (Jain, et al.,
2008). In fact, most individuals who engage in sexual intercourse are likely to contract the virus
at some point during their lifetimes. The majority of these infections will be asymptomatic and
clear within 1to 2 years (Tota, Chevarie-Davis, Richardson, deVries, & Franco, 2011).
Statement of the Problem
Men and HPV. In the 1980’s HPV was considered to be a women’s-only virus because of
its link to cervical cancer (McCabe, 2014). Now the rates of cervical cancer are falling in
women and the effects of HPV in men are rising. Within the United States, men are 25% more
6

likely than women to fall victim to HPV-associated cancers (Sanchez, Tung, Amos, & Lu, 2011).
The ACS currently estimates that over 2,000 new cases of HPV-related cancers in men are
reported annually, thus there has been recent interest in the effects of HPV infection and disease
in men.
A study funded by the National Institutes of Health (NIH) (2008) found that male HPV
infection significantly contributes to infection and cervical disease in women. Scientist have
discovered that HPV is a major cause of anal and penile cancer in men, both heterosexual and
homosexual, and HPV infections among men appear to be similar to the levels of women
(D’Souza & Dempsey, 2011). In fact, men having sex with men (MSM) risk for anal cancer is
comparable to women’s risk for cervical cancer (Wheldon, Daley, Buhi, Nyitray, & Giuliano,
2011). HPV has also been linked to oropharyngeal cancers and genital warts (D’Souza &
Dempsey, 2011).
HPV 16 and 18 have shown to be the most common HPV viral types present in penile, anal
and oropharyngeal cancers (Cubie, 2013; CDC, 2013). Estimates in the United States include
over 2,000 cases of men with anal cancer, almost 2,000 new cases of penile cancer, and
approximately 5,000 new cases of oropharyngeal cancer for men annually (Sanchez, Tung,
Amos, & Lu, 2011; CDC, 2013). Researchers have reported high risk male populations, most
notably men who have sex with men and those men infected with HIV/AIDS, are at an increased
risk for oncogenic HPV viral strains and HPV-associated anal cancers (Sanchez, Tung, Amos, &
Lu, 2011). Previous studies also suggest HPV awareness is on the rise in men; however, many
misconceptions still exist, and knowledge is still limited. High prevalence of HPV among young
adult males supports the assumption that this problem exists because knowledge and awareness
of the virus is limited among young men. This study used a cross-sectional design to sample
7

young males. It involved young men, ages 18 to 26, and the study examined their knowledge of
HPV and HPV related illnesses, their attitudes about the HPV vaccine, their acceptance or
consent to receive the vaccine and their intentions or likelihood to be vaccinated. It is important
for men to understand how to reduce personal risks of HPV infection which may ultimately
reduce the incidence of HPV-related illness in this population and subsequently reduce infection
rates in women.
Purposes of the Study
The purpose of this study was to explore factors associated with differences in
knowledge, attitude and acceptance of the HPV vaccine in young men. In addition this research
measured the intention to receive the HPV vaccine, Gardasil, in a select group of young men
ages 18 to 26 years; measured how knowledgeable young men were about HPV and the vaccine;
and identified favorable or unfavorable attitudes toward accepting the vaccine.
Research Questions
The following questions were addressed in this study:
1. What are young men’s intentions on receiving the HPV vaccine?
2. What are the attitudes of young men toward accepting the HPV vaccine?
3. What factors are associated with differences in attitudes of acceptance for the HPV
vaccine in young men?
4. How knowledgeable are men of HPV, HPV-associated illnesses and HPV prevention?

8

Definition of Terms
Intention. The likelihood of engaging in the act of actually getting the HPV vaccine
(Wheldon, Buhi, & Daley, 2012).
Acceptance. Consenting or approving the HPV vaccine as beneficial (Wang, Phoenix,
Lau, Lau & Lai, 2013).
Knowledge. The awareness of information (Wheldon, Buhi, & Daley, 2012).
Attitude. A persons thoughts or feelings toward something (Aragones, Bruno, & Ganey,
2013).
Significance of the Study
HPV vaccine. Gardasil, a quadrivalent vaccine which protects against four types of
HPV, was licensed in 2006 by the United States Department of Agriculture (USDA) and
approved by the Food and Drug Administration (FDA) for use in women ages 9 to 26 years. In
2009, it was approved for use in preventing HPV 6 and 11 in males ages 9-26 years (CDC,
2013). Gardasil is the only approved vaccine for use in boys and men. In November 2010,
Gardasil was approved for the prevention of anal cancer and neoplasia in males and females
(FDA, 2014). The HPV vaccine has proven to stimulate immunogenicity in males and females
(Dochez, Bogers, Verhelst, & Helen, 2014). This vaccine, Gardasil, is manufactured by Merck
& Co., Incorporation, and is the first vaccine developed to prevent cervical cancer, precancerous
lesions, and genital warts due to HPV (CDC, 2013). Gardasil, which is nearly 90% effective, is
also used for the prevention of vulvar and vaginal cancer, caused by HPV types 6, 11, 16 and 18,
in women. Gardasil is administered in three injections over a six-month period (Merk; Zimet &
9

Rosenthal, 2010). In 2011, the Advisory Committee on Immunization Practices (ACIP)
recommended the routine use of the HPV vaccine in males aged 11 or 12 years, recommended
vaccination of males aged 13 to 21 years who have not been vaccinated previously, and males
aged 22 to 26 years may also be vaccinated (Katz, Kam, Krieger, & Roberto, 2012). According
to the National Immunization Survey data (2014), only 38% of girls and 14% of boys completed
the 3-dose series vaccine in 2013. Despite availability of the vaccine, rates of vaccination
remain low in men (McCabe, 2014)
Getting this information out to men and getting them vaccinated has the potential to be of
great significance in the efforts to decrease the incidence of HPV-associated cancers, especially
in the high risk male population such as men-having-sex-with men and HIV positive men, one of
the largest groups to suffer from HPV-associated cancers (Wheldon, Daley, Buhi, Nyitray, &
Giuliano, 2011). Identifying factors that influence intentions in relation to vaccination in the
male population is necessary to develop prevention strategies.
Although this area of research is increasing, there is limited research published on
readiness to accept the FDA approved HPV vaccine among young men. Thus, the results of this
study may be useful in understanding intentions about receiving immunization against HPV
infection in this population. The knowledge gained by participating in this study may offer a
better quality of life to young men by increasing their awareness of the HPV vaccine and its role
in cancer prevention. It is vital that this information be shared with men because men play a
significant role in the transmission of the virus. They tend to have more sex partners than
females, they visit the doctor less frequently, and they rarely exhibit any symptoms if infected
(Katz, Kam, Krieger, & Roberto, 2012). Vaccinating men can help prevent the transmission of
the virus and will indirectly benefit women.
10

Promoting education and prevention measures regarding HPV is significant in narrowing
the gap between acquisition of the HPV virus and cancer sequelae. Much of the research
regarding the HPV virus focuses on women due to the history of the disease and its connection to
cervical cancer (Cubie, 2013). However, HPV virus in men can cause health problems as well
(e.g. penile cancer, anal cancer, colon cancer, oropharyngeal cancer) (Wang, Mo, Lau, & Lai,
2013).
The association of HPV and its link to different cancers in men has emerged in the media
and literature (Kelly, Leader, Mittermaier, Hornik, & Capella, 2009; Kang & Moneyham, 2010;
Cubie, 2013). In June of 2013, well known actor, Michael Douglas, reported to The Guardian
(2013) that his diagnosis of throat cancer was related to HPV and oral sex. Throat cancer is an
oropharyngeal cancer and refers to a malignancy that occurs in the tonsils, base of the tongue,
and the upper throat (D’Souza & Dempsey, 2011). Douglas later reported that it was cancer of
the tongue, another form of throat cancer. The 2013 Annual Report to the Nation on the Status
of Cancer reported around about 13,000 new cases of oropharyngeal linked to HPV diagnosed in
both men and women in 2009 (the last year of complete available data). Of the new cases, more
than 10,500 were in men. More than 60% of oropharyngeal cancers are caused by HPV,
according to the National Cancer Institute (Jemal et al., 2013).
Knowledge and HPV. A recent study on gender differences found that men did not
perceive themselves to be susceptible to HPV, and another study concluded that the scores for
HPV knowledge were higher for women than for men, and men had a higher level of shame
(Kim, 2013; Jones & Cook, 2008). HPV prevention in both genders is necessary, however the
need for awareness and knowledge of HPV and HPV-related illnesses are at an emergent level
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for males. Evidence suggests that use of HPV vaccination within male populations will help
decrease the incidence of HPV-associated cancers (Kang et al., 2014).
Summary
HPV has become one of the most prevalent sexually transmitted infections. This chapter
identifies the prevalence of the problem and defines the statement of the problem. The specific
purposes and the significance of the study are mentioned. This chapter also includes the research
questions and the definitions of terminology.
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CHAPTER II: REVIEW OF LITERATURE
Chapter two presents the review of literature. First the conceptual framework is
described, followed by the review of literature. Epidemiology of HPV is described. HPVassociated cancers in the male population are presented, followed by literature on knowledge,
intention and attitudes towards acceptance of the vaccine in relation to men. Priority for clinical
research is explained.
Theoretical Framework
The Theory of Planned Behavior by Icek Ajzen has been used throughout research to
examine intentions for a specific behavior. According to the theorist Icek Ajzen, intentions
toward a behavior are influenced by three constructs: attitudes toward the behavior, subjective
norms and perceived behavioral control (Ajzen, 1991).

Perceived behavioral control and

intention are directly related to behavior. Attitude, subjective norms, and perceived behavioral
control are hypothesized to work together to determine intentions to perform a behavior (Ajzen,
1991).
For the purposes of this study, the constructs attitude, acceptance and knowledge are
applicable to examining factors that impact an individual’s intention to be vaccinated.
Determinants that are directly linked to an individual’s behavioral intentions are his or her
attitudes toward performing the behavior (Reynolds & O’Connell, 2012), acceptance of the
vaccine and knowledge of HPV. Attitudes toward the actual behavior are determined by beliefs;
13

if a young man feels that performing a behavior (receiving the HPV vaccine) will lead to a
positive outcome (protecting themselves from HPV related illnesses), they tend to have a more
favorable attitude toward the behavior (Lino et al., 2013). Having a favorable attitude toward the
vaccine may increase their acceptance of the vaccine which directly affects their intentions. The
more knowledge they have about the benefits of the vaccine will also directly affect their
intentions. Intention is defined as the likelihood that the individual engages in the act of actually
getting the HPV vaccine (Wheldon, Buhi, & Daley, 2012).

Figure 1: Modified Theory of Planned Behavior
Epidemiology of HPV
HPV is estimated to be the most common sexually transmitted infection (STI) in the
United States with the highest rates of infection being among sexually active young adults under
the age of 25 (CDC, 2013). HPV currently affects an estimated 20 million people (Jacob,
Bradley, & Barone, 2005; Kahn & Bernstein, 2005; Koshiol, Laurent, & Pimenta, 2004;
14

Moscicki, 2011; CDC, 2013; Schiffman & Castle, 2006). HPV is the second most costly STI,
second only to HIV, far outnumbering other STIs such as chlamydia or gonorrhea (Centers for
Disease Control and National Center for HIV/AIDS, 2009). Human papillomavirus causes
genital warts in men and women and it is associated with anogenital warts and oral cancers
(Wheldon, Buhi, & Daley, 2012). It is estimated that 5.5 million new genital HPV infections
occur in the United States each year (CDC, 2013, Dunne et al., 2007; Frazer et al., 2006; Gerend,
& Magloire, 2008). The link between HPV infections and cervical cancer has been recognized
for more than 20 years and is responsible for over 600,000 cancers each year – higher than any
other cancer associated with an infectious disease (Moscicki, 2011).
Currently, more than 100 papillomaviruses exist. Papillomaviruses are small viruses that
infect cutaneous and mucosal epithelial tissue (Zur Hausen, Fox, Wang, & Parsonnet, 2010).
Papillomaviruses can enter the body through mucous membranes, such as the mouth, eyes, or
throat and they are divided into subgroups of either low or high risk, depending on their
likelihood of causing neoplasia (Dochez, Bogers, Verhelst, & Rees). Low risk HPV infections
(commonly strains 6 and 11) usually cause symptomatic cauliflower-like warts and low-grade
cell changes on the genitals, vagina, cervix, penis or anus. High risk HPV infections (commonly
strains 16 and 18) are associated with anogenital, cervical, and penile cancers in men and
women, however, 40 HPV strains have been identified in the high risk class as potentially
oncogenic or cancer-causing (Sanchez, Tung, Amos, & Lu, 2011).
It is estimated that about 75% of the reproductive-age population will be infected with
HPV at some point in their lives, and that infection is most common in the 15 – 24 age group
(CDC, 2013). In other words, all sexually active individuals are at risk for HPV, unless in a
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monogamous relationship where neither partner has ever been infected with HPV. Unfortunately,
most individuals with HPV will never know that they are infected.
In areas with a high incidence of cervical cancer, men’s sexual behavior is a risk factor
for cervical neoplasia. More recently, scientists have discovered that HPV is linked to cervical
cancer in women and is a major cause of anal and penile cancer in men, both heterosexual and
homosexual (Dochez, Bogers, Verhelst, & Rees, 2014).
HPV-Associated Cancers in the Male Population
Male HPV infections significantly contribute to infection and subsequent cervical disease
in women (Kim, 2012). Much of the information about HPV virus centers on women because of
the connection with cervical cancer. Knowledge not well disseminated is that male HPV
infection significantly contributes to infection and subsequent cervical disease in women (CDC,
2013). HPV virus in men can cause health problems as well in the genitourinary system of males
also. Presently, the HPV virus has been linked to cancers of the anus, penis, and colon.
Oropharyngeal cancers of the tonsils, throat and tongue have also been connected to HPV
(Gross, & Pfister, 2009). More than half of the sexually active men in the United States will
have HPV at some time in their lives which can increase their risk of transmitting the virus and
getting cancer (Kim, 2012). The American Cancer Society estimates that about 1,250 men in the
U. S. were diagnosed with penile cancer in 2008 and about 2,020 men were estimated to have
received a diagnosis of anal cancer in 2009 with a steady predicted increase thereafter (CDC,
2011).
Specific to anal exposure the risk of anal cancer is about 17 times higher in sexually
active gay and bisexual men than in men who have sex only with women. Men who have HIV
16

(human immunodeficiency virus) are at higher risk of exposure to high risk HPV strain with the
potential sequelae of anal cancer (Sanchez, Tung, Amos, & Lu, 2011). The United States as a
whole has a relatively low incidence of anal cancer, but men having sex with men have one of
the highest rates of anal cancer for any given population (CDC, 2009). HPV is estimated to be
responsible for 90% of all anal cancer. HPV associated anal cancers in high-risk populations has
now become more prevalent than HPV associated cervical cancer (Sanchez, Tung, Amos, & Lu,
2011).
In addition to the correlation between HPV and anal cancer, HPV has been found to have
a significant role in other cancers. HPV has been found in cancers of the head, neck, throat, and
oral cavity, in addition to other body sites. A study on penile cancer reported up to 80% of
samples as having a HPV strain present (Sanchez, Tung, Amos, & Lu, 2011). Approximately
40% of all penile tumors are thought to be attributable to HPV infection (Anic & Giuliano,
2011). Penile cancer is rare but it accounts for approximately 0.5% of all cancers in men
worldwide (Parkin & Bray, 2006; CDC, 2013). The disease affects mostly men ages 50-70
years, however it has affected younger males. The incidence of penile cancer in the US is
highest among Hispanics and men who live in the Southern US or areas with high poverty levels
(Bleeker et al., 2009). A quantitative review of studies found HPV present in 45.4% of invasive
penile tumors (Backes, Kurman, Pimenta, & Smith, 2009) and when reviewing the prevalence of
HPV in invasive penile tumors, findings indicated that among those with HPV, HPV 16 was the
most common type detected, followed by HPV 18 and HPV types 6 and11 (Miralles-Guri et al.,
2009).
In addition, high risk strands of HPV has been estimated to be a contributing factor in up
to 25% of oral cancers, such as the mouth, throat, and tongue. HPV is more common in throat
17

cancers, with a significant amount of throat and tonsillar cancers found to be HPV 16 and 18positive (Wheldon, Daley, Buhi, Nyitray, & Giuliano, 2011). Recent research has found that
there is a significantly high and disproportional incidence of HPV-associated cancers in high-risk
male populations (Sanchez, Tung, Amos, & Lu, 2011).
Other types of HPV (6 and 11) viruses rarely cause cancer in men, but they can cause
genital warts. At a given point in time, about 1% of sexually active men in the U.S. will have
genital warts (Gross, & Pfister, 2009). A study that was conducted on men having sex with men
found that prevalence of HPV infection was 48%. When compared to men having sex with
women, men having sex with men were more likely to have oncogenic HPV types and multiple
HPV types present in the anus (Wheldon, Daley, Buhi, Nyitray, & Giuliano, 2011). Men having
sex with men are at an increased risk for these HPV associated cancers.
The state of science on knowledge about HPV infection in men and its relation to
anogenital cancer continues to be limited, this is partially due to the lack in valid methods for
sampling male genitalia, lack in routine preventive methods, and the burden of HPV is far lighter
in men.
Knowledge, Intention, and Attitude Towards Acceptance of the HPV Vaccine
The literature has documented that males of all ages lack knowledge about HPV, the
vaccine, morbidity, transmission and prevention. Acceptance of the HPV vaccine in young
males has been associated with being aware of HPV, having more lifetime sex partners,
perceiving themselves at risk for HPV having peer acceptance of the vaccine and believing that
their parents and peers would encourage them to be vaccinated (Katz, Kam, Kreiger, & Roberto,
2012). Acceptability of the HPV vaccine is on average higher in studies that are conducted with
18

bi-sexual and gay man when compared to heterosexual men (Wheldon, Daley, Buhi, Nyitray, &
Giuliano, 2011; Anic & Giuliano, 2011; Daley et al., 2010; Jones & Cook, 2008). Other studies
conducted with men having sex with men reported a prevalence acceptability ranging from 36%
to 86% (Wang, Phoenix, Lau, Lau, & Lai, 2013). It has been noted that vaccine acceptance is
higher among males who had recommendations from their parents, partners, doctors and peers.
Factors associated with vaccine acceptance among men include knowledge about HPV,
perceived threat, and perceived barriers to the vaccine (Daley et al., 2011). In order for this
vaccine to be effective, acceptance in males is essential.
Attitude toward an outcome is vital when trying to encourage a specific behavior. A
study aimed at the attitudes of men with intentions to receive the HPV vaccine listed intentions
as high and positive when there was repeated exposure to HPV information (Daley et al., 2011),
thus vaccine intentions are driven largely by attitudes toward the vaccine (Wheldon, Daley, Buhi,
Nyitray, & Giuliano, 2011). There is limited theory based research on attitudes toward the HPV
vaccine. Maximizing vaccine uptake in the male population requires research to see what factors
influence their attitudes and acceptance of the HPV vaccine.
HPV awareness appears to be on the rise in men, however knowledge is still limited in
the male population and positive attitudes toward vaccination and prevention is limited as well.
Studies suggest that there is still much confusion and continued lack of awareness surrounding
the difference in genital herpes and HPV infection, the asymptomatic nature of HPV infection,
the link between HPV and cervical cancer, anal cancer, and penile cancer (Gerend, & Magloire,
2008; Jones & Cook, 2008; Katz, Kam, Krieger, & Roberto, 2012). In a study of gender
differences and personal prevention against HPV findings suggest that men are not mindful of
personal susceptibility to HPV (Kim, 2013). However, men who participated in a study geared
19

at increasing knowledge of HPV and the vaccine appeared to be receptive to hearing about the
potential consequences of infection to themselves and their partners (Kim, 2013). Because of the
evidence based information in the literature about HPV and its link to cervical cancer, it’s clear
that this information is well known, however, awareness of other important facts remain limited
in males, such as the link between HPV, genital warts, and various cancers and also, male
susceptibility. Understanding factors such as attitude toward a behavior as it relates to HPV
vaccine intentions are important healthcare concerns. Attitude is considered to be an important
cognitive factor in healthy behavior outcomes (Reynolds & O’Connell, 2012). A positive
attitude toward received HPV information was found to correlate with preventive sexual
behaviors (Kim, 2013). When applying the theory of planned behavior to HPV prevention, it is
assumed that HPV knowledge and attitudes about the HPV vaccine influences intentions related
to HPV prevention. HPV prevention is necessary for men; therefore the factors related to
attitude and knowledge toward HPV prevention is being explored.
Males and Vaccine Acceptance
It has been noted that vaccine acceptance is higher among males who had
recommendations from their parents, partners, doctors and peers. Other factors associated with
vaccine acceptance among men include knowledge about HPV, perceived threat, and perceived
barriers to the vaccine (Daley et al., 2011). In order for this vaccine to be effective, acceptance
in males is essential (Wang, Mo, Lau, Lau, & Lai, 2013; Katz et al., 2012).
Priority for Clinical Research
Most men: 1) do not understand their role in the spread of HPV; 2) do not understand the
link between penile and anal neoplasia and HPV; 3) are not knowledgeable of HPV and HPV
20

prevention; 4) are not aware that having HPV can be asymptomatic; 5) are not aware that having
HPV can not only be detrimental to the health of women but also to their health; 6) Most young,
sexually active men are not aware that there is an HPV vaccine available to them.
Summary
A review of literature was presented in order to indicate how particular research findings
clarify knowledge, acceptance and attitude toward HPV and the HPV vaccine. An
epidemiological view was presented and findings from studies which involve men and their
relation to the virus and vaccine were summarized. The Theory of Planned Behavior is
explained as it relates to the relevance of the study. The theoretical framework is used to guide
some of the research.
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CHAPTER III: METHODOLOGY
Chapter three outlines the research methods for this study. A description of the sample
and setting follow, and inclusion and exclusion criteria, instrumentation, procedures, approval,
and informed consent are presented. Finally, the data analysis is presented. Figure 1 illustrated a
conceptual model of the constructs evaluated in this study.
Sample and Setting
Completing a power analysis with desired effect size of 0.7, 2-sided alpha of .05, and a
desired power of .80, the sample size needed was 70 participants. A random sample of 73
university students was selected. Three were excluded from the sample because they were older
than the age of 26. The sample included young men between the ages of 18 and 26 recruited
from a university in Southwest United States. This University was chosen because of location
and accessibility to the preferred population sample. The selection criteria included males ages
18 to 26 that could read and write English. Men who had received any part of the HPV
vaccination series were excluded from the study.
Instrumentation
Survey. The Human Papillomavirus Immunization Knowledge and Acceptance Survey
(HPVIKAS) (Appendix A) was used to measure the variables knowledge, attitude and
acceptance. It included 17 “true-false” items that operationalized knowledge. HPV knowledge
was measured by items such as “The HPV vaccine cures cervical cancer once it has developed,”
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“HPV can be in a person’s body for many years and you not know it,” “The best way to prevent
being infected with HPV is to avoid genital sex,” “HPV can cause ano- genital cancer.” True
items were coded as 1 and false items as 2. Because of this particular data being categorical a
mean was not calculated for each item; however, a mean score total for percentage correct was
calculated. A plot was created showing the percentage of responses that were correct for each
question. Ten items that are scored on a summative rating scale operationalized attitude and
acceptance. Participants were asked to respond to each statement in terms of their own degree of
agreement or disagreement. Each item was summed together for scoring and means were
calculated. Questions 18 to 22 of the survey measured attitudes of non-acceptance (Table 5).
Mean scores that were less than or equal to 2 were defined as unfavorable attitudes and nonacceptance of the vaccine, however mean scores greater than 2 for this set of questions were
interpreted as favorable for non-acceptance of the vaccine. Questions 23 to 27 of the survey
measured attitudes of acceptance (Table 6). Mean scores that were less than or equal to 2 were
defined as favorable attitudes and acceptance of the vaccine, mean scores greater than 2 were
considered to be unfavorable. Participants were instructed to select one of four responses:
strongly agree, agree, disagree, or strongly disagree. Examples of the questions are “I believe
new vaccines are created to make money for doctors,” “I believe the good of vaccines outweigh
the bad,” “Immunizations protects against or prevents the development of diseases should
contact with the disease occur.” The responses to each item were combined to determine a
favorable or unfavorable attitude of acceptance and a mean was calculated. Content validity and
internal consistency was established by conducting a Cronbach’s alpha coefficient analysis and
was reported as .80. The questionnaire took approximately 15 minutes to complete.
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Demographic. The Demographic questionnaire (Appendix B) was used to describe basic
demographics of the participants. The specific items examined were: race, ethnicity, age, level
of education, parent education level, sexual orientation, religion, doctor visits, and health
insurance. Intention for vaccination was measured by marking a point on an 11-point visual
analogue scale where “0” indicated no intention and “10” indicated a strong intention. Scores
ranging from “0” to “3” were considered low. Scores ranging from 4 to 6 were considered to be
medium or undecided and scores “7” or greater were high intentions. Data were collected
between January 2014 and July 2014.
Procedures
The study and questionnaires were approved by the Institutional Review Board (IRB) for
the University of South Florida before the initiation of the study. One research assistant (RA)
was involved in participant recruitment and questionnaire distribution/data collection and had
credentialed herself with the Collaborative Institutional Training (CITI) Basic Course in the
Protection of Human Research Subjects, as per the regulation of the USF. Permission to use the
survey was gained from the original author.
Recruitment and data collection. The RA was hired to recruit participants, distribute
questionnaires and collect surveys and demographic forms after they were completed. The RA
was given a formal orientation regarding the study, expectations, inclusion criteria, tips on how
to approach and recruit participants. Potential study participants were approached by the RA and
asked to take part in the study. The RA approached participants during breaks in a common
gathering space on the college campus. Only individuals who met inclusion criteria were invited
to participant. Those who agreed to participate signed an IRB approved informed consent and
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were given a copy of the signed consent form. Participants were given a chance to ask questions.
Survey packets were distributed with instructions on completion. The informed consent
statement described the study objectives and steps used to ensure confidentiality and rights.
Participants were informed that they had the right to withdraw from the study at any time. All
data was locked into a file cabinet and will be shredded at the completion of the study. To
maintain compliance and to promote completion of the questionnaire, each participant was
entered into a drawing to receive a $100 gift card. There were a total of 5 drawings. The study
records remained confidential. Identities were not revealed. All information was treated with
confidentiality. An assigned code identification number was assigned to each name. The data
was kept locked in file cabinets in the office until completion of the research study.
Data Analysis
Data analysis and entry was done using SAS version 9.1.3. The program was password
protected. Results are reported as aggregate data only. Statistical analysis answered four
research questions. The following section presents the questions tested and the data analysis
procedures. Descriptive statistics including mean and standard deviation were tabulated for
interval and continuous variables; percentages were tabulated for categorical variables. For
survey instruments, scale scores were created for attitude and acceptance. Univariate analyses
followed by multiple logistic regression analysis were conducted separately for constructs to
assess factors associated with men’s attitudes toward acceptance of the vaccine.
Question one. “What are young men’s’ intentions on receiving the HPV vaccine?” For
this question, means and frequencies were calculated.
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Question two. “What are the attitudes of young men toward accepting the HPV
vaccine?” For this question, means and frequencies were calculated.
Question three. “What factors are associated with differences in attitudes of acceptance
for the HPV vaccine in young men?” Logistic Regression analysis was used to investigate if
race, sexuality or age affected attitude towards acceptance of the HPV vaccine.
Question four. “How knowledgeable are men of HPV, HPV-associated illnesses and
HPV prevention?” For this question, means and frequencies are calculated.
Summary
In this chapter a description of instrumentation for this investigation was presented. The
criteria for selection of the sample, the procedures for the data collection and the methods with
which the data were analyzed was also discussed. The validity of the HPVIKAS was assessed.
Participants were given a questionnaire with a consent form. The consent forms were collected
and given a code for confidentiality purposes. Data were analyzed using descriptive and
analytical methods using SAS 9.1.3.
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CHAPTER IV: RESULTS
Chapter IV first presents the results of this study related to knowledge, attitude and
acceptance of HPV and the HPV vaccine. This is followed by a presentation of the results
according to each research question.
Sample
Seventy men attending a state university in Southwest Florida expressed interest in
participating in the study. All surveys were returned. Demographic data collected included race,
ethnicity, education, age, sexuality and religion. Of 70 respondents, 34 (49%) identified as
white, 14 (20%) as black, and 22 (31%) as other race. Other race included Asian, AmericanIndian or Alaskan Native, and Native Hawaiian or Pacific Islander. There were 56 (80%) selfreported non-Hispanic participants and 14 (20%) self-reported Hispanics. The majority of the
men were greater than the age of 20 years with a mean age of 23. When asked about sexuality,
63 (90%) reported being heterosexual. The majority of the sample self-reported religion as
Christian with 22 (31%) reported being non-religious (Table 1).
Of the 70 respondents, a majority self-reported having health insurance 60 (86%) and 39
(56%) reported going to the doctor regularly. For each participant, regular healthcare visits was
defined as every 6 to 12 months (Table 2).
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Table 1: Frequency and Percentage of Demographics
Variables
Race
White
Black
Other
Ethnicity
Hispanic
Non-Hispanic
Education
<degree
>=degree
Age
<=20
>20
Sexuality
Heterosexual
Other
Religion
Christian
Other religion
No religion

Frequency (F)

Percentage (%)

34
14
22

49
20
31

14
56

20
80

30
40

43
57

20
50

29
71

63
7

90
10

38
10
22

54
14
31

Table 2: Frequency and Percentage of Health Visits
Health Visits
Regular visits with
MD
No regular visits
with MD
Health Insurance
YES
NO

Frequency (F)

Percentage (N)

39

56

30

43

60
10

86
14
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Research Question Number One
To test the first research question, “What are young men’s intentions on receiving the
HPV vaccine”? For this analysis, scores ranging from “0” to “3” were considered low. Scores
ranging from 4 to 6 were considered to be medium or undecided and scores “7” or greater were
high intentions. Intentions to get vaccinated against HPV were low among respondents with a
mean response of 2.6 (SD = 3.09). Only 9 (13%) of the respondents reported a likelihood to
receive vaccination (score of 7 or more). Fifty-one participants (73%) reported low or no
intention to get vaccinated (score of 0 to 3) (Table 3).
Table 3: Sample Means and Standard Deviation for Vaccine Intentions
Level of Intention

N

M

SD

Low < 3

51

0.5

0.9

Medium 4 - 6

10

4.7

0.5

High

9

8.0

1.2

70

2.6

3.1

>7

Overall

Table 4 presents the frequencies and percentages of the participants in reference to the original
scale that measured intention. Thirty participants (42%) chose zero, 10 (14%) chose one, 7
(10%) participants chose 5 and only 2 (3%) chose 10 when asked how likely they were to receive
the HPV vaccine. In summary, this data supports low intention (scores of 0-3) to receive
vaccination for HPV in young men.
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Table 4: Frequency Table for Intention
Level of Intention

Frequency (F)

Percent (%)

0

30

42

1

10

14

2

6

10

3

5

10

4

3

3

5

7

10

6

0

0

7

4

5

8

3

3

9

0

0

10

2

3

Research Question Number Two
To test question 2, “What are the attitudes of young men toward accepting or not
accepting the HPV vaccine?” On a 1 to 4 scale (from Strongly Agree to Strongly Disagree),
ratings for attitude toward vaccine non-acceptance were high (meaning a tendency to disagree
with the statements). As seen in Table 5, mean scores for all non-acceptance items were around
3, indicating that respondents generally disagreed with negative statements, such as, “I believe
that vaccines are created to make money for the government.”
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Table 5: Means and Standard Deviation for Attitude Towards Vaccine Non-Acceptance

Questions: Attitude for vaccine none acceptance
Q18: I believe vaccines are created to make
money for doctors

M
3.24

SD
0.71

Q19: I believe getting several vaccines at one
time causes problems

2.92

0.76

Q20: Religion plays a part in my decision making
about the vaccine

3.51

0.76

Q21: I believe vaccines are created to make money
for the government

3.14

0.89

Q22: I believe vaccines cause other illnesses

3.04

0.89

On a 1 to 4 scale (from Strongly Agree to Strongly Disagree), ratings of attitude towards
vaccine acceptance were relatively low (meaning a tendency to agree with the statements). As
seen in Table 6, mean scores for all but one acceptance item were around 2 which corresponds to
the Descriptor “agree.” Thus, participants tended to agree with statements such as “I believe the
good of vaccines outweighs the bad.” Of note, there was overall disagreement with the statement
“HPV is not serious enough for a vaccine.”
Figure 2 shows percentages of answers for the questions that determine acceptance for
the HPV vaccine. Approximately 60% of the sample disagree with the following statements,
“receiving several vaccines at one time causes a problem; religion plays a part in my decision
making about the HPV vaccine; vaccines are created to make money for the government; and
that vaccines cause other illnesses.
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Table 6: Means and Standard Deviations for Attitude for Vaccine Acceptance
Questions: Attitude for vaccine acceptance
I believe the vaccine prevents cervical cancer and
Q23: genital warts

M

SD

2.12

0.83

Q24: I believe the good of vaccines outweigh the bad

1.65

0.76

Immunizations protect against or prevent diseases
Q25: should contact with the disease occur

1.77

0.80

People should have the right to refuse vaccines for
Q26: certain reasons

2.04

0.88

Q27:: HPV is not serious enough for a vaccine

3.45

0.65

A majority (more than 50%) of respondents agreed that the vaccine prevents cervical
cancer and genital warts. Close to 50% agreed that the good of the vaccine outweighs the bad.
A little more than 40% reported an attitude of acceptance for immunizations protecting against or
preventing the development of diseases. Only about 9% agree that patients should have the right
to refuse vaccinations because of medical, religious, or personal reasons. More than fifty percent
of respondents strongly disagree with the statement “HPV is not serious enough for a vaccine.”
64.3

Percentages(%)

70
60
50
40
30
20
10
0

55.7

51.4

48.6
38.6

41.4
37.1
20 20

11.4
1.4
Q18

4.3
Q19

38.6
35.7

25.7
7.1
2.9

15.7
5.7

Q20
Strongly agree

47.1
44.3

agree

Q23

disagree

4.34.3
Q24

5.75.7
Q25

strongly dissagree

Figure 2: Percentages for Attitudes of Acceptance and None Acceptance
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41.4

37.7

22.9

7.1

5.7
Q22

53.6

30
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20

Q21

48.6
40

5.7
Q26

8.7
0
Q27

Research Question Number Three
To test question three, “What factors are associated with differences in attitudes of
acceptance for the HPV vaccine in young men?” As stated above, a logistic regression analysis
was used to examine factors associated with differences in attitudes of acceptance. There were
no significant independent predictors associated with favorable attitudes of acceptance for the
HPV vaccine in males ages 18 to 26 years (Table 7). While not statistically significant, the
strongest suggestion for factors potentially associated with greater acceptance of the HPV
vaccine (e.g. perhaps assessed with a larger sample) included Hispanic ethnicity, no religious
affiliation, black race, and lack of insurance.
Research Question Number Four
How knowledgeable are men of HPV, HPV associated illnesses, and HPV prevention?
As shown in Figure 3 and Table 8, most respondents (91%) correctly answered the question “the
HPV vaccine does not cure cervical cancer once it has developed”. Fifty-eight percent answered
correctly for, “HPV vaccine prevents cervical cancer from developing.” Sixty-nine percent of
respondents correctly answered the knowledge question that asked if “girls have to receive three
shots of the HPV vaccine.” However, the knowledge response to Q4 was practically an even
split (49% correct and 51% incorrect) when asked if boys have to receive three shots of the HPV
vaccine. Unfortunately, the aggregate percentage HPV knowledge score was less than 70%
when asked: Q6, the best time to get the vaccine is before any possible exposure to the virus; Q7,
the vaccine prevents all genital warts; Q9, the virus can be in a person’s body for many years and
not know; Q11 another way to decrease the risk of getting HPV is being in a long-term
relationship; Q12 people who are infected with HPV will always have symptoms; Q13 there is
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no cure once you are infected with HPV; and Q16 the vaccine is recommended for all boys
between the ages of 9 and 26.
In summary, knowledge for HPV was relatively low (i.e. below 70%) among this group
of male college age students. The cohort when sampled was knowledgeable about the literature
on women and HPV but lower vaccine knowledge was noted in regards to males and HPV.
Summary
Four research questions were investigated in this research study. Each of these was
concerned with the HPV vaccine and constructs that have an influence on attitudes and
acceptance of the HPV vaccine such as age, race and sexuality. Intentions of young men to
receive the vaccine were also analyzed.
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Figure 3: Display of Percentage of Correct Responses to Knowledge Questions
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Table 7: Logistic Regression with Multivirate Analyses for Predicting Acceptance
Variable

N (% that accepts)

OR

95% CI

p

White

15 (44)

1

Black

6 (43)

1.54

0.33 – 7.28

0.306

Other

6 (27)

0.43

0.10 – 1.9

0.190

0.77 – 22.76

0.096

0.22 – 3.55

0.854

0.16 – 3.97

0.793

0.10 – 5.36

0.744

Race

Ethnicity
Non-Hispanic

20 (36)

1

Hispanic

7 (50)

4.2

>=degree

15 (38)

1

<degree

12 (40)

0.88

>20

19 (38)

1

<=20

8 (40)

0.81

Other

4 (57)

1

Heterosexual

23 (37)

0.71

Other religion

3 (30)

1

Christianity

13 (34)

0.68

0.06 – 7.21

0.414

No religion

11 (50)

1.64

0.16 – 16.28

0.352

Regular visits

13 (33)

1

No regular visits

13 (43)

1.12

0.30 – 4.15

0.968

Yes

21 (35)

1

No

6 (60)

3.10

0.5 – 19.29

0.225

Education

Age

Sexuality

Religion

Health

Insurance

p = <0.05*.

35

Table 8: HPV Knowledge Questions and Percent Correct for Each Item
Question
1. The HPV vaccine
cures cervical cancer
once it has developed
2. Girls should get three
shots of the vaccine

(%)
91

Question
10. The HPV vaccine prevents
cervical cancer from developing

(%)
54

59

11. Boys should get three shots
of the vaccine

67

3. Girls who get the
69
HPV vaccine do not
need to get pap smears

12. The best time to get the
vaccine is before any possible
exposure to the virus

91

4. The vaccine prevents
ALL genital warts

49

13. The vaccine prevents
pregnancy

70

5. HPV can be in a
person’s body for
many years and you
not know it
6. Another way to
decrease risk for
getting HPV is to be
in a long term
relationship
7. There is no cure once
you are infected with
HPV

93

14. The best way to prevent
being infected with HPV is to
avoid genital sex

69

91

15. People who are infected
with HPV will always have
symptoms

37

93

16. HPV can cause anogenital
(anal/butt) cancer

71

8. It is not possible to get 97
infected with HPV
from the vaccine

17. The HPV vaccine is
recommended for all boys
between the age of 9 and 26
years of age

81

9. It is recommended
that men older than 30
years ask their
healthcare provider
for the HPV test

Total Percent Correct

74

90
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CHAPTER V: DISCUSSION, CONCLUSION, AND IMPLICATIONS FOR NURSING
This final chapter presents the syntheses of the research results including the discussion
of the findings, conclusion, and implications for nursing. This study presents the summary of the
knowledge of HPV and HPV prevention in young men ages 18 to 26, and their attitudes for
acceptance of the vaccine. This study also explored demographic factors and how they may
predict an individual’s acceptance of the vaccine. This study provided minimal detail of college
student’s awareness about HPV and it highlighted predictors that may be associated with HPV
vaccine acceptance.
Summary of the Study
A cross-sectional survey design was used for this study. Descriptive statistics and
logistic regression was used to assess knowledge and acceptance of the HPV vaccine and factors
that may predict a favorable attitude towards acceptance. Participants were 70 men attending a
state university in the Southwest United States. Descriptive data for the sample were obtained
with frequencies, percentages, means, and standard deviations. The sample predominately
represented white (49%) male college aged students. Seventy one percent of the sample was
aged 20 years or older with a mean age of 23.
Discussion
The science linking HPV to sexual and reproductive health cancers is well established.
The most common STI worldwide, HPV, has potential sequelae of cervical, penile and anal
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cancer. Specifically, high risk subtypes, HPV 16 and 18 are linked to sexual and reproductive
health cancers in men and women. There has been recent interest and little research in the effects
of HPV infections and disease in men. This research adds to the science of HPV and men.
Research question number one. The first research question investigated men’s
intention on receiving the HPV vaccine. One of the most notable findings from this study is the
majority of participants who do not intend to receive the vaccine. Perhaps this is because of the
limited marketing about the vaccine availability in this population and lack of HPV awareness,
including their perceived susceptibility to the virus. Because of this finding, the incidence of
HPV and HPV related illnesses may be expected to increase among sexually active young adults
unless intervention strategies are put into place. Another explanation as to why intentions to get
vaccinated were low could be because parents of participants may not be familiar with the
vaccine. This age range of men relies heavily upon health advice from their parents. Parental
barriers include limited access to tailored information for patients, cost, cultural barriers, and
perceived risks outweighing perceived benefits could affect intentions to receive the vaccine as
well as acceptance of the vaccine. Targeting parents and providing them with information on the
HPV vaccine could be a strategy to be tested to potentially increase rates of intention. On
another note, a study about attitudes toward intention to receive the vaccine reported that
respondents stated they would be more willing to receive the vaccine if it was recommended by
their clinician (Kang & Moneyham, 2013). A study conducted by Moffitt Cancer Center found
that fewer than 15% of physicians recommend this vaccine to young men (McCabe, 2014).
Healthcare providers are important sources of information and parents value information from
physicians. The construct intention in relation to young men and what influences their intention
should be explored further. Increasing this cohort’s intentions on receiving the vaccine would be
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expected to aid in the prevention of HPV. Exploring additional factors beyond demographics
that may be related to a young man’s intention to be vaccinated should be considered. The
success rates of this vaccine will likely depend, in large part, on physician’s ability to
recommend the HPV vaccine.
Research question number two. Attitudes for accepting the vaccine were generally
favorable for young men overall. However, this finding was largely at odds with the finding of
low intentions actually receive the vaccine by study participants. Findings from this study were
not consistent with similar research findings that vaccine intentions are driven largely by
attitudes toward the vaccine and beliefs about the outcomes of being vaccinated (Wheldon et al.,
2011). Although the HPV vaccine has no real identified difference in side effects when
compared to other vaccines, reports of adverse reactions are a concern (Kang & Moneyham,
2010). Some physicians have stated concerns of safety, as well, which is a preventing factor
from recommending the HPV vaccine. Minorities indicated a non-significant trend towards
more favorable attitudes of acceptance for the vaccine when compared to whites. Whereas this
was not a significant finding; it does however suggest a rationale to explore attitudes of levels of
acceptance among whites. On a positive note, the fact that minorities were certainly no less and
suggested a higher likelihood of accepting the vaccine than whites is notable that current data
supports minorities being disproportionally affected by HPV (Aragones, Bruno, & Gany, 2013).
Having minorities being potentially more likely accept the vaccine is a step in the right direction
given overall higher risk status. Also, there was a non-significant suggestion of homosexuals
having a more favorable attitude of acceptance when compared to heterosexuals. This
suggestion is encouraging since research has shown that homosexuals are considered high risk
for contracting oncogenic strains, HPV 16 and 18. High acceptance will hopefully yield high
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intentions to get vaccinated among this population. The Theory of Planned Behavior has shown
to be a valid model for predicting behaviors conceptually; however, it did not support my
assumption that high acceptance and favorable attitudes will lead to high intentions. This finding
was probably due to the participants rushing through the questions and not accurately
understanding the items.
Research question number three. Further investigation is needed to determine specific
factors, ideally those that are modifiable, that significantly influence acceptance of the HPV
vaccine in young men. The findings of the present study suggest that strategies aimed at HPV
prevention should attempt to increase marketing and awareness of the vaccine which may result
in an increase of acceptance. Education is needed on the dynamics of the vaccine and what role
it plays in prevention of HPV in men and how it can indirectly increase prevention in women.
The majority of HPV studies have aimed prevention efforts to women and gay men. In a study
about gender differences, findings showed that men do not perceive themselves susceptible to
HPV which could explain why findings from this study suggest that heterosexual appear to be
less likely to accept the vaccine. This suggests that HPV prevention is not a high priority for
them and subsequently this decision can, in the worst case, affect mortality rates in both genders.
Minorities altogether had a favorable attitude for acceptance of the vaccine when compared to
whites. Those with no formal religious affiliation provided a suggestion of being more likely to
accept the vaccine. It has been documented that vaccine acceptance is higher among males who
had recommendations from their parents, partners, doctors and peers. In the present study, there
were little relationships between men who did and did not go to the doctor regularly and their
likelihood to accept the vaccine. In this study, men who reported having insurance nonsignificantly reported being less likely to accept the vaccine. This apparent trend may suggest
40

misconceptions about whether insurance will pay for the vaccine. Highlighting some of the
findings in this analysis should be considered when exploring interventions for vaccine
acceptance that are aimed at this population. Decreasing the transmission of HPV is a high
priority when attempting to reduce the incidence of cervical cancer, anal cancer, neck cancer and
penile cancer.
Research question number four. An intriguing finding was the high proportion of
respondents who think HPV infection can occur with HPV vaccination. Perhaps this finding
sheds some light as to why many individuals have low or no intention for receiving the vaccine.
This study supports the fact that there are still poor understandings about the HPV vaccine;
however, an exception is the fact that more than half of the respondents understand that the
vaccine prevents cervical cancer, yet does not cure it. An important issue is to enhance
knowledge and HPV awareness in this population. Future studies need to clarify the knowledge
of the HPV vaccine in young adult males. HPV education is necessary to enhance the intentions
of young men to prevent HPV.
Young men between the ages of 18 and 26 appear to have low knowledge of HPV and
HPV prevention. They were aware that there is no cure for HPV and the best way to prevent
contraction of the virus is avoiding genital sex. They were also aware that having the virus does
not always mean one will be symptomatic. However, their understanding of the HPV vaccine
was limited in the aspect of the number of shots needed in order for the vaccine to be effective.
Anogenital cancer was addressed and findings showed that they know HPV can lead to sexual
and reproductive cancers. More than half of the participants thought that receiving the vaccine
can lead to cancer, which is an obvious misconception. Studies have revealed that the HPV virus
is linked to cancers of the anus, penis, colon, tonsils, throat and tongue (Gross & Pfister, 2009);
41

however, the HPV vaccine was approved in 2009 to prevent anal and penile cancers in men.
Evidence suggests that use of HPV vaccination within male populations will help decrease the
incidence of HPV-associated cancers (Kang et al., 2014). This warrants the need to educate
young men on the dynamics of the vaccine and its benefits as a priority. Healthcare providers
need to continue to stress HPV’s link to anogenital cancer as well as other cancers and encourage
prevention. It’s important that we continue to educate young women on the benefits of the
vaccine and we need to urge them to aid in the awareness of HPV to men.
Although the research in relation to HPV has been centered toward women, the risk of
anal cancer among gay males is comparable to women’s risk for cervical cancer (Wheldon et al.,
2011). These findings alone are serious enough to encourage health care providers to promote
marketing for this vaccine. This study also indicates awareness of HPV is on the rise in this
population (i. e. young adults) however there are still many misconceptions about the vaccine.
HPV education is very necessary in this population, which is consistent with findings of previous
studies. Given that HPV prevention should begin at the primary prevention level, it should be
stated that being in a monogamous relationship, getting vaccinated before possible exposure to
the virus and receiving the entire series of vaccines are important factors in controlling the risk of
HPV.
Implications for nursing. This research has important implications for nursing. The
findings suggest that health education is needed to enhance knowledge and awareness of HPV
and the HPV vaccine. The dynamics of the vaccine and behavioral recommendations for HPV
prevention and the importance of regular doctor visits should be emphasized. Nurses at local
health departments and clinics should provide brief educational interventions within the
community. When Gardasil was first introduced to the market for girls, the marketing campaign
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was evident and visible. The same structure and models should be used for boys. Even when
attempting to increase the awareness of HPV in males, it may not translate into HPV prevention
behaviors. Nurse educators should engage interventions that include repeated exposure to
information about HPV vaccination in males. Nurse educators should target fathers and partner
with them to help increase vaccination in young males. This may result in higher intentions to
get vaccinated. Young men value the opinion of parents so there should be interventions aimed
at getting parents involved in HPV prevention. There is a substantial need for educational
campaigns to disseminate knowledge about HPV and personal consequences of HPV infection.
Given the low levels of HPV knowledge, increasing the awareness is a start. Future research
should include other populations involved in making decisions about getting vaccinated,
including adolescents, parents and young women. There should be qualitative studies conducted
to help healthcare providers understand what influences young men’s intentions and there needs
to be more research data on the efficacy of the vaccine and its benefits. Interventions aimed at
having partners see the clinician together could help decrease barriers.
Limitations. Limitations in this study should be considered when presenting the
findings. Although attempts were made to recruit a racially diverse sample, the sample as a
whole was small and there was not equal representation among races. It was a convenience
sample so the findings may generalize only to young college men. Studies with much larger
sample sizes are needed to determine whether HPV awareness has increased in student
populations and within the community. Another limitation of this study could be that only young
men ages 18 to 26 years were examined and it did not include ages 9 to 17. The HPV vaccine
has been approved for use in young men ages 9 to 26 by the FDA. Clinical trials are being
evaluated to determine the feasibility of the HPV vaccine in older men; future studies should
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assess this cohort’s receptivity to the vaccine and identify effective ways to inform men about
HPV prevention and HPV vaccination.
Conclusions
The present study examined the knowledge, attitudes of acceptance, factors related to
vaccine acceptance, and intentions to prevent HPV in young men ages 18 to 26. The findings
suggest that there are still misconceptions about the vaccine in this population. To promote the
HPV vaccine among men, healthcare providers need to correct perceptions of the vaccine in
general by discussing vaccination with parents and engaging in discussion with young men. In
addition, there may be important differences in terms of race, religion, age and sexuality when it
comes to acceptance of the vaccine and intentions on being vaccinated. Further study is required
to identify both modifiable and non-modifiable factors associated with acceptance and intention
to receive the HPV vaccine. While HPV education is very much necessary for young men,
enhancing awareness about HPV prevention and reducing risky sex behaviors are necessary for
the entire college population. There is a need to further increase the understanding of the
prevalence and incidence of HPV related cancers that affect both genders. There should be
efforts to increase the intentions to get vaccinated by changing attitudes toward HPV vaccination
and helping men to make informed decisions.
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